Primary Myelofibrosis Terminated Phase 2 Trials for Nivolumab (DB09035)

Also known as: Myelofibrosis, Primary / Osteomyelofibrosis / Chronic idiopathic myelofibrosis

IndicationStatusPhase
DBCOND0001581 (Primary Myelofibrosis)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02421354Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera MyelofibrosisTreatment